Exploration on the Mechanism of Shengmai Powder in Treating Diabetic Cardiomyopathy Based on Network Pharmacology
Objective To explore the material basis and mechanism of Shengmai Powder in the treatment of diabetic cardiomyopathy(DCM)using the network pharmacology.Methods The effective components and targets of Shengmai Powder were obtained from TCMSP database,BATMAN-TCM database,TCMID database and UniProt database;the DCM related targets were obtained from GeneCards,OMIM,PharmGKB and DrugBank databases.The common targets of Shengmai Powder and DCM were obtained by intersection of the two.A drug component-disease target network was constructed with Cytoscape 3.8.0 software,and the protein-protein interaction(PPI)relationship was constructed using STRING database,and the PPI network diagram was drawn.The PPI network diagram was imported into Cytoscape 3.8.0 for topology analysis,and the core targets were screened out.R 4.2.0 software was used for GO function and KEGG pathway enrichment analysis.Results A total of 52 effective components of Shengmai Powder were obtained,including N-trans-feruloyltyramine,kaempferol,orchinol,ruscogenin,methyl ophiopogonanone B,methyl ophiopogonanone A,ophiopogonanone A,ophiopogonanone E,β-sitosterol,and Stigmasterol.A total of 195 common targets related to the treatment of DCM were identified for Shengmai Powder.The core targets included STAT3,JUN,AKT1,RELA,MAPK14,and others.GO analysis revealed 2 348 biological processes,74 cellular components,and 197 molecular functions.The main processes involved responses to external biological stimuli,aging,and responses of cells to non-biological stimuli.KEGG analysis identified 177 related signaling pathways,including lipid and atherosclerosis,fluid shear stress and atherosclerosis,AGE-RAGE signaling pathway,IL-17 signaling pathway,and PI3K-Akt signaling pathway.Conclusion Shengmai Powder can target STAT3,AKT1 and MAPK14 through high flavonoid of kaempferol,β-sitosterol,stigmasterol and methyl ophiopogonanone B,and AGE-RAGE signaling pathway,IL-17 signaling pathway and PI3K-Akt signaling pathway are mediated to regulate inflammation,oxidative stress and myocardial fibrosis to prevent and treat DCM.
国家科技期刊平台
NSTL
万方数据
维普
